Conditions: Diabetes Mellitus, Type 2
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 66
Healthy volunteers: no

Brief summary:
The main purpose of this study is to determine the safety of LY2922470, taken as oral capsules, once or twice daily for approximately 28 days, in participants with diabetes. It also aims to determine how long the drug stays in the body and how it affects blood sugar levels. A screening appointment is required within 28 days before the start of the study and a follow up appointment is required approximately 14 days after the last study dose is taken.

Detailed description:

Arms:
arm 1: Multiple oral dose of placebo administered to participants with diabetes once or twice daily for 28 days arm 2: Multiple ascending dose of LY292470 (starting at 60 mg) administered orally to participants with diabetes once or twice daily for 28 days

Interventions: intervention 1: Placebo intervention 2: LY2922470
Intervention descriptions: intervention 1: Administered orally as capsules intervention 2: Administered orally as capsules

Protocol document: